KPNA2

Across TCGA pan-cancer cohorts, KPNA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KPNA2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KPNA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KPNA2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where KPNA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.330	0.784	.002	41	view →
LUAD	OS	Median	II,III,IV	0.337	0.908	.002	14	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.523	.002	10	view →
CCRCC	OS	Median	III,IV	0.538	0.865	.009	8	view →
OV	DFS	Median	All	0.861	1.000	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KPNA2–PDAC (OS)

Open the PDAC breakdown →